Liposomal technologies for silybin delivery to the liver i n patients with non-alcoholic fatty liver disease

The aim of the study is to evaluate the effectiveness and safety of liposomal technologies in the treatment of non-alcoholic fatty liver disease (NAFLD) using Silybin (Lipoliv) as an example. Materials and Methods. The authors conducted a randomized placebo-controlled study approved by the ethics committee. The study included 111 subjects with NAFLD, aged 18-65. Lipoliv therapy (experimental group) or placebo therapy (control group) lasted for 12 weeks, the trial subjects received 1 capsule per day. The authors evaluated success rates, such as steatohepatitis activity (AST, ALT), severity of liver steatosis (transient elastography with controlled attenuation parameter), quality of life (SF-36 questionnaire); and safety profile: adverse events. Statistical analysis was carried out using the StatTech v. 1.2.0. Results. The subjects of the experimental group demonstrated a significant decrease in ALT (p